{"filing":{"accession_number":"0001193125-26-299290","cik":"0001958777","ticker":"FBLG","company_name":"FibroBiologics, Inc.","form":"8-K","filing_date":"2026-07-09","report_date":null,"primary_document":"fblg-20260702.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1958777/000119312526299290/fblg-20260702.htm"},"events":[{"id":17214,"run_id":15400,"accession_number":"0001193125-26-299290","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.94,"summary":"FibroBiologics appointed Kathleen Rubins, Ph.D., a retired NASA astronaut and microbiologist, as a Class III director effective July 8, 2026, with assignment to the Audit, Compensation, and Governance committees. Dr. Rubins brings distinguished scientific credentials and has served on the company's Scientific Advisory Board since 2022.","company_name":"FibroBiologics, Inc.","ticker":"FBLG","filing_date":"2026-07-09","form":"8-K","submitted_at":null,"items":[{"id":15584,"accession_number":"0001193125-26-299290","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the appointment of Kathleen Rubins, Ph.D. as a Class III director effective July 8, 2026, with assignment to three board committees (Audit, Compensation, and Governance). While the section also mentions Matt Link's resignation on July 2, 2026, the substantive focus and detail of the disclosure centers on Dr. Rubins' appointment, her qualifications (retired NASA astronaut, microbiologist, founding director of University of Pittsburgh institute), and her committee assignments. The appointment of a qualified director to multiple committees is material to investors assessing board composition and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T13:05:03.340085+00:00","company_name":"","ticker":null,"filing_date":""},{"id":15585,"accession_number":"0001193125-26-299290","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Dr. Kathleen \"Kate\" Rubins, Ph.D. to FibroBiologics' Board of Directors. The press release emphasizes her distinguished background as a retired NASA astronaut, microbiologist, and founding director of the University of Pittsburgh Trivedi Institute, and notes she has been an invaluable member of the Scientific Advisory Board since 2022. This is a material board appointment that would affect a reasonable investor's assessment of the company's governance and scientific direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T13:05:03.340085+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":15584,"accession_number":"0001193125-26-299290","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the appointment of Kathleen Rubins, Ph.D. as a Class III director effective July 8, 2026, with assignment to three board committees (Audit, Compensation, and Governance). While the section also mentions Matt Link's resignation on July 2, 2026, the substantive focus and detail of the disclosure centers on Dr. Rubins' appointment, her qualifications (retired NASA astronaut, microbiologist, founding director of University of Pittsburgh institute), and her committee assignments. The appointment of a qualified director to multiple committees is material to investors assessing board composition and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T13:05:03.340085+00:00","company_name":"FibroBiologics, Inc.","ticker":"FBLG","filing_date":"2026-07-09"},{"id":15585,"accession_number":"0001193125-26-299290","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Dr. Kathleen \"Kate\" Rubins, Ph.D. to FibroBiologics' Board of Directors. The press release emphasizes her distinguished background as a retired NASA astronaut, microbiologist, and founding director of the University of Pittsburgh Trivedi Institute, and notes she has been an invaluable member of the Scientific Advisory Board since 2022. This is a material board appointment that would affect a reasonable investor's assessment of the company's governance and scientific direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T13:05:03.340085+00:00","company_name":"FibroBiologics, Inc.","ticker":"FBLG","filing_date":"2026-07-09"}]}